Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Barriers towards the publication of academic drug trials. Follow-up of trials approved by the Danish Medicines Agency.

Berendt L, Petersen LG, Bach KF, Poulsen HE, Dalhoff K.

PLoS One. 2017 May 9;12(5):e0172581. doi: 10.1371/journal.pone.0172581. eCollection 2017.

2.

From protocol to published report: a study of consistency in the reporting of academic drug trials.

Berendt L, Callréus T, Petersen LG, Bach KF, Poulsen HE, Dalhoff K.

Trials. 2016 Feb 19;17:100. doi: 10.1186/s13063-016-1189-4.

3.

Methodological characteristics of academic clinical drug trials--a retrospective cohort study of applications to the Danish Medicines Agency 1993-2005.

Berendt L, Håkansson C, Bach KF, Andreasen PB, Petersen LG, Andersen E, Poulsen HE, Dalhoff K.

Br J Clin Pharmacol. 2010 Nov;70(5):729-35. doi: 10.1111/j.1365-2125.2010.03755.x.

4.

[Effect of the GCP Directive on academic drug trials].

Berendt L, Håkansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, Andersen E, Poulsen HE.

Ugeskr Laeger. 2008 Aug 11;170(33):2437-9. Danish.

PMID:
18761825
5.

Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006.

Berendt L, Håkansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, Andersen E, Poulsen HE.

BMJ. 2008 Jan 5;336(7634):33-5. Epub 2007 Dec 6.

Supplemental Content

Loading ...
Support Center